Evofem Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 27, 2024

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except par value and share data)

	December 31,
2023 · 2022
Assets
Current assets:
Cash and cash equivalents	$	-	$2,769
Restricted cash		580	1,207
Trade accounts receivable, net		5,738	1,126
Inventories		1,697	5,379
Prepaid and other current assets		1,195	2,218
Total current assets		9,210	12,699
Property and equipment, net		1,203	3,940
Operating lease right-of-use assets		106	4,406
Other noncurrent assets		35	4,118
Total assets		$10,554	$25,163
Liabilities, convertible preferred stock and stockholders’ deficit
Current liabilities:
Accounts payable		$17,020	$14,984
Convertible notes payable carried at fair value (Note 4)		14,731	39,416
Convertible notes payable - Adjuvant (Note 4)		28,537	26,268
Accrued expenses		4,227	4,124
Accrued compensation		2,609	2,175
Operating lease liabilities - current		97	2,311
Derivative liabilities		1,926	1,676
Other current liabilities		3,316	2,876
Total current liabilities		72,463	93,830
Operating lease liabilities - non-current		8	3,133
Total liabilities		72,471	96,963
Commitments and contingencies (Note 7)		-	-
Convertible and redeemable preferred stock, $0.0001 par value, Senior to common stock
Series B-1, B-2, C, E-1, and F-1 convertible preferred stock, 5,000, 5,000, 1,700, 2,300, and 95,000 shares authorized; 1,874 shares of E-1 and 22,280 shares of F-1 issued and outstanding at December 31, 2023; no other shares issued and outstanding at December 31, 2023 or 2022		4,593	-
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 or 2022			-
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 20,007,799 and 984,786 shares issued and outstanding as of December 31, 2023 and 2022, respectively		2	-
Additional paid-in capital		823,036	817,367
Accumulated other comprehensive income (loss)		(849)	49,527
Accumulated deficit		(888,699)	(938,694)
Total stockholders’ deficit		(66,510)	(71,800)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit		$10,554	$25,163

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.